Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US court rules Apotex's Fosamax appeal moot

This article was originally published in Scrip

Executive Summary

The US Court of Appeals for the Federal Circuit has determined in a July 16th decision that the Merck & Co Apotex Fosamax suit is rendered moot by two factual developments brought to the court’s attention after oral argument – including the fact that Apotex no longer suffers a delay in entering the generic marketplace for alendronate sodium tablets. Generic versions of alendronate were approved for sale in the US in February.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts